Profile data is unavailable for this security.
About the company
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
- Revenue in USD (TTM)12.67bn
- Net income in USD827.68m
- Incorporated1994
- Employees70.00k
- LocationDaVita Inc2000 16th StDENVER 80202-5158United StatesUSA
- Phone+1 (310) 536-2668
- Fax+1 (302) 636-5454
- Websitehttps://www.davita.com/
Mergers & acquisitions
| Acquired company | DVA:NYQ since announced | Transaction value |
|---|---|---|
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Brazil | 30.11% | 300.00m |
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Ecuador | 30.11% | -- |
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Colombia | 30.11% | -- |
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Chile | 30.11% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemed Corp | 2.38bn | 301.73m | 8.28bn | 15.09k | 27.95 | 6.68 | 22.73 | 3.48 | 19.78 | 19.78 | 155.82 | 82.78 | 1.43 | 136.49 | 13.04 | 157,566.50 | 18.11 | 19.53 | 21.79 | 24.64 | 35.66 | 34.60 | 12.69 | 12.60 | 1.81 | -- | 0.00 | 8.15 | 6.06 | 4.90 | 9.17 | 5.80 | 1.46 | 6.10 |
| Ensign Group Inc | 4.11bn | 239.98m | 8.29bn | 35.30k | 35.01 | 4.74 | 25.79 | 2.02 | 4.13 | 4.13 | 70.86 | 30.50 | 0.9433 | -- | 8.01 | 116,391.30 | 5.52 | 6.45 | 6.63 | 7.88 | 21.19 | 22.32 | 5.85 | 6.48 | -- | -- | 0.0773 | 6.56 | 23.27 | 16.28 | -6.80 | 28.62 | 4.40 | 5.02 |
| Encompass Health Corp | 5.22bn | 431.20m | 9.97bn | 22.36k | 23.41 | 5.09 | 11.66 | 1.91 | 4.23 | 4.11 | 51.10 | 19.45 | 0.8396 | -- | 9.38 | 233,270.70 | 9.07 | 6.37 | 11.87 | 7.94 | 95.49 | 95.58 | 10.80 | 9.16 | -- | 6.14 | 0.486 | 30.78 | 10.41 | 2.34 | 41.31 | 4.49 | 16.60 | -10.42 |
| Universal Health Services, Inc. | 15.42bn | 1.03bn | 13.04bn | 73.35k | 13.14 | 1.97 | 8.01 | 0.846 | 15.03 | 15.03 | 225.85 | 100.14 | 1.09 | -- | 6.93 | 210,194.40 | 7.41 | 6.44 | 8.68 | 7.63 | -- | -- | 6.78 | 6.55 | 1.28 | 7.70 | 0.4105 | 6.06 | 6.59 | 5.80 | 6.32 | -1.47 | 1.17 | 14.87 |
| Davita Inc | 12.67bn | 827.68m | 13.23bn | 70.00k | 17.40 | 34.48 | 7.05 | 1.04 | 9.28 | 9.28 | 141.50 | 4.68 | 0.7357 | 71.34 | 5.90 | 180,951.60 | 6.58 | 5.62 | 8.88 | 7.45 | 32.80 | 30.70 | 8.94 | 8.33 | 1.33 | 4.77 | 0.8115 | -- | 4.57 | 1.26 | 26.44 | 2.33 | -10.47 | -- |
| Tenet Healthcare Corp | 20.97bn | 3.13bn | 14.44bn | 78.14k | 4.86 | 3.77 | 3.02 | 0.6885 | 31.26 | 31.26 | 209.81 | 40.32 | 0.7364 | 9.49 | 7.15 | 268,376.30 | 13.86 | 3.61 | 20.23 | 5.09 | 82.61 | 82.97 | 18.83 | 4.95 | 1.52 | 5.37 | 0.6145 | 0.00 | 7.17 | 2.33 | 49.02 | 41.42 | 4.01 | -- |
| Molina Healthcare Inc | 39.20bn | 1.14bn | 16.85bn | 18.00k | 14.95 | 3.52 | 12.72 | 0.4299 | 19.70 | 19.70 | 674.97 | 83.68 | 2.56 | -- | 13.71 | 2,177,722.00 | 7.47 | 7.62 | 16.58 | 16.80 | 16.12 | 15.99 | 2.92 | 3.04 | -- | 14.83 | 0.3465 | 0.00 | 6.56 | 12.52 | 37.75 | 9.06 | 22.87 | -- |
| Quest Diagnostics Inc | 9.54bn | 838.00m | 18.01bn | 40.00k | 21.66 | 2.65 | 13.49 | 1.89 | 7.45 | 7.45 | 84.79 | 60.79 | 0.645 | 34.77 | 7.18 | 238,475.00 | 5.87 | 9.28 | 6.77 | 10.81 | 32.94 | 36.64 | 9.10 | 12.97 | 1.17 | 8.87 | 0.4746 | 25.07 | -6.38 | 4.20 | -9.77 | 3.40 | 1.27 | 7.43 |
| Holder | Shares | % Held |
|---|---|---|
| Berkshire Hathaway, Inc. (Investment Management)as of 30 Sep 2024 | 36.10m | 44.02% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.16m | 6.30% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.13m | 3.82% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.41m | 2.94% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.16m | 1.42% |
| LSV Asset Managementas of 30 Sep 2024 | 1.05m | 1.29% |
| Invesco Capital Management LLCas of 30 Sep 2024 | 989.04k | 1.21% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 872.91k | 1.07% |
| Gates Capital Management, Inc.as of 30 Sep 2024 | 721.20k | 0.88% |
| BlackRock Advisors (UK) Ltd.as of 30 Sep 2024 | 698.29k | 0.85% |
